KTOV Stock Price, News & Analysis

KTOV

Company Description

KTOV (Nasdaq: KTOV) is a publicly traded company.

KTOV stock has gained 459.3% over the past year.

This page provides a comprehensive overview of KTOV stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

+459.28%

Performance 1 year

$0.0

Market Cap

0.0

Shares outstanding

KTOV (KTOV) stock. Over the past 12 months, the stock has gained 459.3%.

Latest News

View All

December 10, 2020

+0.24%

Kitov Announces Name Change to Purple Biotech Ltd.

November 11, 2020

+5.58%

Kitov Pharma to Participate in November Investor Conferences

conferences

November 9, 2020

+0.73%

Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb

clinical trial

October 27, 2020

+6.39%

Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219

October 16, 2020

+3.34%

New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference

September 8, 2020

-2.44%

Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients

clinical trial

KTOV has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include conferences, clinical trial, earnings. View all KTOV news →

SEC Filings

View All

No SEC filings available for KTOV.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months